# Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-13 23:29 UTC · Category: Business · Sources: 9 · Current Velocity: 7.5

## Executive Summary
Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.

## Intelligence Brief
Q32 Bio reported topline results from Part B of the SIGNAL-AA clinical trial for Bempikibart. The 36-week data indicates that 40% of patients achieved a key hair regrowth mark, with the treatment positioned as a potential rival to current JAK inhibitors.


Coverage from outlets including Fierce Biotech, Yahoo Finance, and Qz.com highlights a substantial increase in Q32 Bio stock value, with reports varying between 60% and 83%. Oppenheimer has reportedly raised the company's price target to $40, citing the trial results and a cash-rich balance sheet as factors in recent market activity.


Observers are looking toward future phases of the SIGNAL-AA trial. Coverage does not yet specify the timeline for subsequent trial stages or potential regulatory submission dates.

## Verified Facts & Key Claims
### What is the primary driver of Q32 Bio's recent stock movement?
Market activity follows the announcement of positive 36-week topline results from Part B of the SIGNAL-AA clinical trial for the drug Bempikibart.

### How effective was Bempikibart in the reported trial?
According to trial data, 40% of patients achieved a key hair regrowth mark at the 36-week interval.

### What is the analyst outlook on Q32 Bio?
Oppenheimer has maintained its position on the company and raised the price target to $40.

## Key People, Organizations & Locations
Experimental, Price Target Raised, Oppenheimer, JAK, QTTB Stock Rockets On Volatility And Cash-Rich Balance Sheet, QTTB Bempikibart, QTTB Maintained, Q32 Bio Announces Positive, Topline Results, Part B of the SIGNAL-AA Clinical Trial of Bempikibart

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Stock Titan | Experimental alopecia areata drug sees 40% of patients hit key hair regrowth mark | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMivAFBVV95cUxNWGV3ZldabEcwTzUwZXBRS1RLUmNtTkhDZlNDVTJzNWFMMUxZeG9nb2pqaGNWX3haeGdDbmNlQTZQbXFmamJjWHZtUjBHd192bWpqeTFlTGY2am0xeXlzVUhJcGJIUUluTzNfUUJuQmVfb0tpZE1YMWtQU3JIblVUSE5xa0p5WUI4c3d6X3ZOYTVkSmVNYndzdEsyakQxekh4UEdvRi01Y3k2S2trZ3NnbllmbVBWdmFHdk9HRA?oc=5) |
| qz.com | Q32 Bio stock surges 83% on positive alopecia drug trial data | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMiekFVX3lxTE9DaDl4Q3RXLWFjRzNweGwzSVlISThISDVQSS00S1BCd2xsTlc1c3JZaENWYkZUMUNFYXV4SF9YRmhOM29kZ29iTC1YcWh5S3EtV2ltdVp2MmlxM2JmYjBvZDNfeDdVUFYwWDFiVnhOYXp5YVc4bk9YTlpB?oc=5) |
| Yahoo Finance | Q32 Bio Shares Jump 60% After Positive Mid-Stage Alopecia Trial Results (QTTB) | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNE5DcWp1WnY1YjJZc05ZZzFGbGRRN0w4akpXU0x3c0JLYXpIRmlMdVVlZVRBZURhUE5FdWJ0SUdkaEZGcEsyems0WEdCUk9hbEFiQmN3UG1UdGxFNXVHbldYZDhIMEFZOHhwb0ZYM0xQWldLWnQwbnlyZjVwUEluX0UySl9TcWlXOG1F?oc=5) |
| PR Newswire | Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMikgJBVV95cUxNZ0pPcTM1eGFJbURnaGEtNGQ4S3RNSDVFdU1yYkRxUzAwREpyci1CWmdZbmNaRzdwM0VWempmUVhmQVRxTHpoUG4wV1djOFdfQVl6QzUwaC1XYVM4Vm1CWTZNdC02QnZFTEJERDBmak50NFVucUktM2NrU2dqZ0FWSHZZRWgyWVZXeFpEVHNlVzVER1RaQm9xT2xrMnV5SUVKblNSNzZSMGFIeDNrbjdCTUNSZlRZODJUbFZPODBoQlR6ZHNpOFdwWExlOF9vZ25ydkNsX2ctZHBkMFZudGZIbGNHeFhSMkJNcmlUd3JsRFZwLTlGZHZLNDNhNTFNNGs2RzFoS0tDT2J2cjM3cDNIaWVR?oc=5) |
| The Motley Fool | Why Q32 Bio Stock Skyrocketed Today | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxOb216NjlQSmhyTzFWejFLRkQ5YVlpNTZPTmhacExKS2dYc3ZLUnpScWs1WVFablVtclI4aUZUVlN2aGd6LXd4T1V2eWYtNXFzajNfengybW1IT24yNE8zOC1BWlVFTGVIaXgzYWZMQUcwY1VEUFdlQ0I4NWZqVGZELVlsdm8?oc=5) |
| StocksToTrade | QTTB Stock Rockets On Volatility And Cash-Rich Balance Sheet | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMickFVX3lxTFBqMm5hdnVraER4MHJ3WVN3NmJqd3ZTaEhZcjh0T3p5S0tJdnNOYzg5OERsTWZMSU9jVjhiX2lya1VzV2hYdE5pQWhJcTFkNEJZU3g0SVdOSWhJTDFzYWU4S1lHd3dUTEpUQ1RiQmZLNWlZZw?oc=5) |
| TradingView | QTTB: Bempikibart achieved meaningful hair regrowth and safety in severe alopecia areata at 36 weeks | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMijwJBVV95cUxPMEpDYkJhdVJodUE3ZkpDWi16Y3htNjhwanlfemlldWVaanJyOFgzNS11VGtwemVneU1oMUxBSXR2bkZKWmJFVjhnSHB6X1VBcGFhMlVSd01PdTZlVmJnYjc2SlpPZGtvcnAzUFIzQzZPQ1k0TEotNFBtenhpSTVpT2x4MWJzZTVqTldkNy1YUmF6aE94WWhrM1BreUdEM01GQmlSUTNtd05jVGZWTklwWVJHYzVJRE1pVVY3NWJiSEIxdDY0aDdHb1ZBcjRUMGdta3NGalQ0bFpBbTlQekJ2bUhYNy10Rk54MmlmYnVPYkliZDFOdHdXTzlLekMwSTY3Sk91N19Wd2dEVERPMUFZ?oc=5) |
| GuruFocus | QTTB Maintained by Oppenheimer -- Price Target Raised to $40 | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxPWmtaYWotYjZyY3hwajRTMDB5SlpqeDdKTHlkZGxxQndFWFFCODBNQ1BDWVhEbTJCRUtYRnE1a2l0czVwVWZoWFZCV2Z0eE4zUnVzSE9oLXF5REFadmhCblllVDVLM3pVR1RNWGkzVXRmSldaU0VqQ0hxR2Zxd0dpbVdSUUVFZGhmeWNVQkxSLUU0M2U0aTMyM01oUQ?oc=5) |
| Yahoo Finance | Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxPdm5MM0xEbHdaVUo4TDFYSWhlTTBSVW44T3ZmQzNwRDQzYm95dTBaTHRPdnhVRU02N1BjNVBDWnI4bWxPUEVZaU1Ic3M4RGUwd0ZUcDFKa1g1NXlSb3ROdG1wLW5pZFJMUUlfei1CUUFGY0NIdDFLS3QzU3dPcFVEYjlDcERXOWlncFIybnF6dy1Lb0JZ?oc=5) |
| Fierce Biotech | Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors | 2026-07-13 14:40 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxORGxNQ2lnelhuVGh5d3VjWkFrMlg4NWZwUWxYVGNrTEs3S2VyTzJpd3RnSTJHY0hhdVB2eFVhbmNaNHhRdDZQcklmeUFpQmdDWkQ0U05XU3RoZjg5WkRVbkNYNmFjb21KYmNabENyRkI3dGFHZzN2djBicFUyZkhQc2d2bGFPQndCTThqSlZKN1B0SFdVdEUyRXFTWVFMTVdnanFkR0NGbFlTUkE?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-13/q32-s-stock-jumps-60-on-latest-phase-2-alopecia-data-for-potential-rival-to-jak*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*